Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
05 oct. 2022 08h05 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS...
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
30 sept. 2022 06h50 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by...
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
02 sept. 2022 08h09 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product...
Immuneering Announces Participation in September Investor Conferences
25 août 2022 06h50 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates...
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights
10 août 2022 16h05 HE
|
Immuneering Corporation
IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first patient in planned Phase 1/2a clinical trial expected in Q4 2022 ...
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022
06 juil. 2022 06h50 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates...
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104
26 mai 2022 17h26 HE
|
Immuneering Corporation
IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies showing the potential for broad activity across...
Immuneering Announces Participation in Upcoming Investor Conferences
20 mai 2022 06h50 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates...
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights
10 mai 2022 06h30 HE
|
Immuneering Corporation
IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022 IND filing for IMM-6-415, designed to sensitize resistant tumors to select immunotherapies,...
Immuneering Announces Participation in Citi’s Biopharma VIRTUAL Co-Panel Day
05 mai 2022 06h50 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates...